Reply To: Traders Market Weekly: Brand New Year, what is Ahead?

#69551
Truman
Participant

Boston Scientific (BSX 57.02, +0.74, +1.3%): Initiates AVANT GUARD Clinical Trial to Evaluate FARAPULSE™ Pulsed Field Ablation System as First-Line Treatment for Persistent Atrial Fibrillation